Besides the selectivity for VHL and SETD2, TGX221 also targets CDKN2A and PTEN mutations that, albeit not unique in ccRCC, play critical roles in a variety of cancers22, 23. This evidence concerns the gene PTEN and nonpapillary renal cell carcinoma.